Biogen Inc. (1BIIB)
MTA
Closed
Aug 24, 2026
Day's Range
183.9252 wk Range
116.40Overview - 1BIIB - Biogen Inc.
Key Statistics
Valuation
Enterprise Value
29.69B
P/E (Trailing)
‪38.95‬
PEG Ratio
‪-0.45‬
Price / Sales (TTM)
‪2.76‬
Price / Book
‪1.71‬
EV / EBITDA
‪10.34‬
Profitability
Gross Margin
‪71.60%‬
Profit Margin
‪8.32%‬
Operating Margin
‪25.05%‬
Return on Assets
‪5.20%‬
Return on Equity
‪4.57%‬
Ownership
Shares Outstanding
147.70M
Float
147.21M
Held by Insiders
‪0.18%‬
Held by Institutions
‪99.51%‬
Price stats
Beta
‪0.16‬
50-Day Avg
‪179.06‬
200-Day Avg
‪162.50‬
Dividends
Payout Ratio
‪0.00%‬
Market Cap - 1BIIB - Biogen Inc.
Peers - 1BIIB - Biogen Inc.
Peer Comparison
Compared with companies in Drug Manufacturers - General listed on MTA.
- 1BIIBMTABiogen Inc.23.34BMarket Cap+35.90%52-week change38.96P/E (Trailing)‪8.32%‬Profit Margin
- 1LLYMTAEli Lilly and Company853.56BMarket Cap+43.34%52-week change42.55P/E (Trailing)‪33.52%‬Profit Margin
- 1JNJMTAJohnson & Johnson428.46BMarket Cap+35.82%52-week change31.56P/E (Trailing)‪21.48%‬Profit Margin
- 1ABBVMTAAbbVie Inc.344.57BMarket Cap+21.59%52-week change75.36P/E (Trailing)‪9.80%‬Profit Margin
- 1ROMTARoche Holding AG294.63BMarket Cap+26.89%52-week change24.74P/E (Trailing)‪19.60%‬Profit Margin
- 1MRKXMTAMerck & Co., Inc.240.41BMarket Cap+43.93%52-week change125.16P/E (Trailing)‪4.76%‬Profit Margin
- 1NOVNMTANovartis AG238.75BMarket Cap+22.16%52-week change24.05P/E (Trailing)‪22.50%‬Profit Margin
Profile Summary - 1BIIB - Biogen Inc.
About
Biogen Inc. is a biotechnology company that discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company offers products such as TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
